• LinkedIn
  • YouTube
  • Facebook
  • Twitter
InnoSer
  • CRO Services
        • Drug Development
          • Target Validation
          • Hit to Lead
          • Lead Optimization
          • Preclinical Development Services
          • Pathology
          • Mouse Models
        • Facility Management & Support
          • Colony Management
          • Facility Management
          • Sanitation and Cryopreservation
          • ISAP – InnoSer Acceleration Program
  • Disease Models
    • Disease Areas
    • Cardio-metabolic
    • Nephrology
    • Rare Diseases
      • Fragile X syndrome (Fmr1)
      • Vanishing White Matter (Eif2b)
      • Charcot Marie Tooth Disease Type 1A (PMP22)
      • Infantile Epileptic Encephalopathy (STXBP1/Munc18-1)
      • Polycystic Kidney Disease
    • Neurology
      • Alzheimer’s Disease
      • Parkinson’s Disease
      • ALS Disease
      • Multiple Sclerosis
      • Spasticity
      • Ageing
    • Immuno-oncology
  • Resources
    • News
    • Conferences
    • Privacy Policy
  • About
    • About InnoSer
    • Contact
    • Team
    • Scientific Board
    • 3R's Policy
    • Vacancies
Select Page
In Vitro & In Vivo Parkinson’s Disease Models: Understanding Their Role in Preclinical Drug Development 

In Vitro & In Vivo Parkinson’s Disease Models: Understanding Their Role in Preclinical Drug Development 

Jun 6, 2023

Parkinson’s disease (PD) is a complex neurodegenerative disorder that affects millions of people worldwide. Different experimental models recapitulate distinct pathophysiological features of PD. Selecting the most appropriate model for a specific research question is...
A novel inflammation and fibrosis model in the field of NASH & drug repurposing

A novel inflammation and fibrosis model in the field of NASH & drug repurposing

Apr 11, 2023

Nonalcoholic steatohepatitis  Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression and the development of cirrhosis. Given the high attrition rates, repurposing of...
InnoSer expands preclinical cancer readout capabilities through acquisition of new imagers.

InnoSer expands preclinical cancer readout capabilities through acquisition of new imagers.

Sep 15, 2022

Getting closer to understanding cancer through the adoption of technological advancements is crucial in providing deeper insights for our customers. By building robust and reliable dossiers for promising drug candidates moving into clinical trials, we can help our...
Discussing innovation and the PDX/O platform at SINERGIA Summer School

Discussing innovation and the PDX/O platform at SINERGIA Summer School

Jun 12, 2022

We strive to stay at the forefront of biotechnological developments and to constantly incorporate innovation in our offerings – this is essential to be able to develop more reliable drug development platforms and avoid high drug attrition rates. Study director...
Facility management and preclinical services discussed at the FELASA Congress

Facility management and preclinical services discussed at the FELASA Congress

Jun 5, 2022

Animal testing has played a critical role in the development of drugs, enabling us to ultimately obtain data which serves as a foundation to be able to deliver safe and effective drugs to patients. We are an AAALAC accredited organization committed to the 3Rs, by...
Get to know our preclinical drug development services at Knowledge for growth

Get to know our preclinical drug development services at Knowledge for growth

May 10, 2022

We are constantly looking for opportunities to exchange and develop ideas, as they are the foundation for scientific advances and innovation. In addition to our collaboration with academic and commercial partners, attending conferences such as Knowledge for Growth...
« Older Entries

Recent Posts

  • Novel Translational Readout: Auditory Event-Related Potentials EEG-Recording in Fragile X Syndrome Model 
  • Accelerating ALS Drug Development: InnoSer’s Available In Vivo Models for Preclinical Research
  • In Vitro & In Vivo Parkinson’s Disease Models: Understanding Their Role in Preclinical Drug Development 
  • Choosing The Right ADPKD Model for Advancing your Rare Disease Research
  • A novel inflammation and fibrosis model in the field of NASH & drug repurposing

Subscribe To Newsletter

By signing up, you agree to receive promotional emails from InnoSer.

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please check our privacy page.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing.

  • LinkedIn
  • YouTube
  • Facebook
  • Twitter
Copyright InnoSer 2020-2022
This website uses cookies to improve your experience. Information about your use of the site is also shared with Google for analyzing traffic to this site. You can opt-out if you wish. Cookie settingsACCEPT Privacy policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT